According to filings with the U.S. Securities and Exchange Commission, Simergent is raising up to $8,101,331.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Steve Lindo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Simergent
Simergent is developing affordable, easy to use home dialysis systems for developed and emerging markets. Simergent is committed to putting patient’s needs first with a best-in-class automated peritoneal dialysis device. Our Archimedes system will allow patients to live a normal life, socializing with family and friends even while receiving treatment, rather than spending every other day in a dialysis clinic. It contains patented features designed with the goal of reducing peritonitis, while making it easy to train new patients to use it. Its filling and draining pressures are much lower than current devices, while maintaining accurate control over volume measurements. In a recent market research study, current PD patients ranked Archimedes features with a 98% appeal score, versus 29%-36% appeal score for features similar to competitors’ peritoneal dialysis devices. Archimedes solves the problems that patients and clinicians care most about so patients can live a normal life.

To learn more about Simergent, visit http://www.simergent.com/

Contact:
Steve Lindo, Chief Executive Officer
214-557-5868
https://www.linkedin.com/in/sjlindo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.